Mektovi
Payments companies reported to CMS as associated with Mektovi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Mektovi, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Mektovi
These are the largest totals companies reported as associated with Mektovi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sajeve Thomas | Orlando, FL | Hematology & Oncology | $52,717.81 |
| Jeanelle King | Miami, FL | Physician Assistant | $39,328.68 |
| Hashem Younes | Pittsburgh, PA | Hematology & Oncology | $36,304.30 |
| Omid Hamid | Santa Monica, CA | Hematology & Oncology | $20,452.96 |
| Maen Abdelrahim | Houston, TX | Medical Oncology | $19,931.34 |
| Yana Najjar | Washington, DC | $18,509.48 | |
| Sarmen Sarkissian | Mission Hills, CA | Hematology & Oncology | $18,311.28 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $18,176.25 |
| Misagh Karimi | Newport Beach, CA | Hematology & Oncology | $15,378.52 |
| Tarek Chidiac | Columbus, OH | Hematology & Oncology | $15,274.01 |
Prescribed Mektovi?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.